Beyond phosphate binding: The effect of binder therapy on novel biomarkers may have clinical implications for the management of chronic kidney disease patients

Kidney International

Volumn 76, Issue SUPPL. 114, 2009, Pages

  Striker, Gary E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ENDOTOXIN; FETUIN A; FIBROBLAST GROWTH FACTOR 23; OXIDIZING AGENT; PHOSPHATE BINDING AGENT; SEVELAMER; UREMIC TOXIN;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIET; DISEASE COURSE; EDITORIAL; HEART PROTECTION; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; INTESTINE FLORA; KIDNEY CLEARANCE; KIDNEY FUNCTION; MACROPHAGE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL;

EID: 71949089346     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.400     Document Type: Editorial

References (10)

1. Himmelfarb J, McMonagle E, McMenamin E. Plasma protein thiol oxidation and carbonyl formation in chronic renal failure. Kidney Int 2000; 58: 2571-2578.
2. Himmelfarb J, McMonagle E. Manifestations of oxidant stress in uremia. Blood Purif 2001; 19: 200-205.
3. Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep 2007; 7: 235-241. (Pubitemid 46951921)
4. Yamada K, Fujimoto S, Tokura T et al. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. Renal Fail 2005; 27: 361-365. (Pubitemid 40993682)
5. Shantouf R, Budoff MJ, Ahmadi N et al. Effects of sevelamer and calciumbased phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol 2008; 28: 275-279.
6. Ferramosca E, Burke S, Chasan-Taber S et al. Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 2005; 149: 820-825. (Pubitemid 40718876)
7. Caglar K, Yilmaz MI, Saglam M et al. Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. Clin J Am Soc Nephrol 2008; 3: 61-68.
8. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252. (Pubitemid 34754068)
9. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824. (Pubitemid 43169927)
10. Pizzarelli F, Lauretani F, Bandinelli S et al. Predictivity of survival according to different equations for estimating renal function in communitydwelling elderly subjects. Nephrol Dial Transplant 2009; 24: 1197-1205.